CT55 and chronic myelogenous leukemia, BCR-ABL1 positive: A recent study reported that CT55 is a potential novel immune target for achieving treatment-free remission in chronic myeloid leukemia patients27, which prompted us to investigate whether CT55 affects immune and inflammatory responses during the process of CAC.